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ABSTRACT 
The use of radiolabeled antibodies, immunoglobulin fragments and other proteins are an 
increasingly important sector of research for diagnostic imaging and targeted radiotherapy in 
Nuclear Medicine. As with all radiopharmaceuticals, efficient radiochemistry is a prerequisite to 
clinical translation. For proteins, variations in the primary amino acid sequence, the secondary 
structures and tertiary folds, as well as differences in size, charge, polarity, lipophilicity, and the 
presence of post-translational modifications, add complexity to the system. The choice of 
radionuclide or chelate, and their impact on the thermodynamic, kinetic and metabolic stability of 
a radiotracer has attracted much attention but the chemistry by which the radionuclide is 
conjugated to the protein scaffold is of equal importance. Recently, a wealth of creative advances 
in protein ligation methods based on chemical, photochemical and enzyme-mediated processes 
have emerged. As radiochemists explore alternative bioconjugation strategies, this article 
considers their potential impact on radiotracer design. 
Keywords: Bioconjugation, immuno-PET, antibodies, protein ligation, enzymes, 
photoradiochemistry 
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INTRODUCTION 
It has long been established that the precise nature of the chemical linker used to couple a small-
molecule or peptide to a radiometal complex can have a profound impact on the properties of a 
radiotracer (1). Our recent work on coupling the 68Ga-DFO-complex via two different linker 
strategies to the urea-based Glu-NH-C(O)-NH-Lys group for imaging prostate specific membrane 
antigen (PSMA) illustrates this point (2,3). When compared with the clinically translated agent, 
68Ga-PSMA-11, dramatic differences were observed in cellular binding, tumor targeting and 
whole-body distribution and excretion profiles of 68Ga-DFO-Nsucc-PSMA and 68Ga-DFO-pNCS-
Bn-PSMA – radiotracers constructed using N-succinyl and thiourea-based chemistries, 
respectively. Specifically, the small and less lipophilic N-succinyl linker reduced PSMA binding 
affinity with a dissociation constant from cellular assays (Kd-value) of 26.4  7.8 nM compared 
with a value of 13.6  2.6 nM for the compound with the pNCS-Bn linker, and 2.89  0.55 nM for 
68Ga-PSMA-11. These differences in PSMA binding affinity also led to pronounced differences 
the uptake, retention and excretion of these three radiotracers in mice bearing LNCaP tumors. 
For radiotracers based on antibodies, and other proteins, less is known about the impact 
that linker methodology may have on the stability, pharmacokinetics and target specificity of the 
ensuing radiotracer. Until recently, our collective experience with radiolabeled antibodies has 
relied on a small handful of conjugation routes. Classic chemistries typically involve reactions of 
native cysteine or lysine residues (4–11). For example, thiolate groups of cysteine side chains 
readily undergo Michael addition reactions with maleimide groups, and the -NH2 group of lysine 
side chains participate in nucleophilic reactions using activated esters or isothiocyanates. An 
overview of the essential structure of an antibody and various options for performing conjugation 
chemistry is shown in Fig. 1 (4,12). Note that highlighted functionalization sites (positions 1 to 6) 
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are not intended to be a comprehensive list of all chemically accessible features but rather give a 
flavor of the types of conjugation reactions that are currently being explored. The selection does 
not include the wide array of ‘click’ methods for which the reader is referred to the detailed review 
by Meyer et al.(13) The following sections discuss some of the features of recent chemical, 
photochemical and enzyme-mediated conjugation reactions with a particular emphasis on 
applications with antibodies (14,15). Some of the methods described are yet to be applied in 
radiosynthesis but illustrate the scope of reactions that harbor potential for future use.  
CHEMICAL FUNCTIONALIZATION METHODS 
In spite of the diverse range of new bioconjugation methods, it remains true that the vast majority 
of synthetic transformations rely on the native chemistry of cysteine (sulfhydryl) and lysine 
(primary amine) side-chains. Some of the reactions of these two amino acids are presented in Fig. 
2. 
In general, reactions at cysteines involve either derivatization of a single residue or 
sequential reduction of disulfides followed by substrate-induced re-bridging (Fig. 2A). In all cases, 
the chemistry features nucleophilic substitution or addition-elimination mechanisms using 
reagents bearing labile leaving groups. Conjugation with maleimide groups has been a mainstay 
of conjugation chemistry for many decades. Indeed, two United States Federal Drug 
Administration approved antibody-drug conjugates (ADCs) – brentuximab vedotin (Adcetris®, 
Seattle Genetics) and trastuzumab emtansine (Kadcyla®, Genentech / Roche) – employ this 
conjugation strategy. However, in cysteine-rich environments, the reaction is potentially reversible 
and experience has found that such conjugates are susceptible to chemical and metabolic instability 
in vivo leading to questions over long-term stability (16). Stability is of particular concern for 
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radiotracers based on antibodies which require extended circulation times for peak accumulation 
in tumor lesions and clearance from background organs. Notably, stability of maleimide-
conjugated in vivo can be improved by ensuring that the 5-membered ring hydrolyses to the ring-
opened succinic acid thioether – the rate of which can be increased by the use of electron-
withdrawing substituents on the nitrogen atom (16). Related agents based on 18F have also been 
introduced (17). Since two bonds are usually better than one (from a thermodynamic and kinetic 
perspective) disulfide re-bridging is also an attractive strategy to potentially overcome stability-
related issues associated with cysteine functionalization (18). Re-bridging can be achieved with 
the reagents shown (Fig. 2A [right]) but variants of the photochemically induced thiol-ene and 
thiol-yne radical based coupling reactions are also potential options (15).  
In many aspects, lysine-based conjugation reactions are more readily accessible than 
cysteine functionalization. A typical IgG1 human antibody has around 90 lysines, many of which 
are solvent exposed and chemically accessible (19). In contrast, IgG1 antibodies like trastuzumab 
have 16 cysteine residues, all of which are involved in inter- and intra-chain disulfide bridges. 
Only the four inter-chain disulfides are easily modified but require reduction before the thiolate 
residues become accessible for functionalization. Hence, lysine-based reactions are the most 
prevalent method used for chemical modification of antibodies (Fig. 2B). Radiolabeling antibodies 
at lysine residues takes one of two mechanistic forms: either i) direct conjugation of the radiolabel 
to the -NH2 group, or ii) a ‘tag-and-modify’ approach in which the side chain is first tagged with 
another reactive group that facilitates bioorthogonal coupling to a tertiary reagent (c.f. numerous 
‘click’-based conjugation and pre-targeting studies) (13,20–22). From a clinical perspective, the 
high reproducibility and efficiency of lysine modification using activated esters or isothiocyanate-
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based reagents make these the most prevalent methods used in the synthesis of clinical-grade 
radiolabelled antibodies (23).  
An interesting variation on the ‘tag-and-modify’ route involves the use of radiolabeled 
sugars to functionalize proteins (24–27). For instance, in 2015, Rashidan et al. reported that 18F-
FDG could be substituted at the anomeric (C1) position using tetrazine reagents bearing an RO-
NH2 group (Fig. 2C) (25). Reaction of the amine with the ring-opened aldehyde isomer of 18F-
FDG (catalyzed by the addition of p-phenylenediamine, pPDA) gave a stable oxime intermediate 
that was subsequently used in site-specific radiolabeling of an anti-Class II Major Histone 
Complex (MHC) antibody. This work also featured the use of site-specific enzyme-mediated 
tagging of the antibody using sortase-A (vide infra) to incorporate the transcyclooctene partner for 
strain-promoted inverse electron demand Diels Alder ‘click’ conjugation.  
A related ‘tag-and-modify’ approach was reported by Vugts et al. who used traceless 
Staudinger ligation to label antibodies that were pre-modified with an azide group (28). A series 
of phosphine-based reagents were synthesized to allow conjugation of the chelates DFO and 
DOTA, or an 123I-radiolabeled cubyl-phosphine to the mAb via the traceless approach. Use of the 
traceless Staudinger ligation was also explored in the context of antibody pre-targeting. Although 
derivatization of proteins using Staudinger ligation chemistry was successful, a number of 
drawbacks including slow biomolecular conjugation kinetics and metabolic instability of the 
phosphine groups in vivo will likely preclude further use of this chemistry for pre-targeting (29).   
As an alternative conjugation method, our group recently reported the development of a 
photochemically-mediated conjugation and radiolabeling reaction based on chelates bearing aryl 
azide groups (Fig. 2D) (30–32). The process is distinct from almost all other conjugation 
chemistries in that the active reagent is formed in situ by irradiating the samples with ultra violet 
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light (~365 nm). Under irradiation, aryl azides spontaneously release N2(g) and undergo rapid 
isomerization to give a ketenimine intermediate. The unique feature of this mechanism is that the 
ketenimine intermediate acts as a preferential electrophile for primary and secondary amines, 
thereby facilitating chemo-selective, lysine-based conjugation. Conceptually, photochemistry is 
an attractive foundation for bioconjugation reactions because, i) photoactivation can occur at 
wavelengths where most proteins do not absorb and also on a short time scale that minimizes 
potential damage to the underlying protein, ii) productive protein ligation occurs with high 
quantum efficiency and under ambient conditions so no heating is required, iii) the aryl azide 
reagents are cheap, easy to synthesize, and thermally stable up to ~60 oC permitting long-term 
storage, and iv) photoradiochemistry permits the simultaneous, one-pot conjugation and 
radiolabeling of non-purified antibodies (i.e. antibodies in their standard GMP formulation) in <20 
min. A combination of stability measurements, cellular assays, temporal PET imaging and 
biodistribution studies confirmed that the 89Zr-DFO-azepin-trastuzumab obtained by 
photoradiochemistry was biochemically equivalent to 89Zr-DFO-Nsucc-trastuzumab produced by 
a conventional thermochemical conjugation route (Fig. 3) (32,33). Recent work by Poot et al. 
introduced fully automated radiolabeling and purification of 89Zr-radiolabelled antibodies, but as 
with manual synthesis, the approach still relies on the use of pre-conjugated protein (34). An 
additional advantage of our photoradiochemical method is that the conjugation step is potentially 
amenable to full automation which opens the possibility of using non-modified proteins as starting 
materials. 
Native chemical ligation (NCL) was originally introduced in the 1990s by Kent and co-
workers (Fig. 2E) (14,35,36). The NCL process is straight-forward and involves a reversible trans-
esterification reaction initiated by nucleophilic attack of an N-terminal Cys-thiolate on an 
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engineered C-terminal thioester. The resulting activated thioester then undergoes a spontaneous 
and irreversible, intramolecular S-to-N acyl shift under physiological conditions to yield a peptide 
bond linkage. This approach is an elegant, chemo-specific and regio-specific method for facile 
derivatization of proteins but to the best of our knowledge, has yet to be applied in radiotracer 
design. The caveat is that C-terminal thioesters are required but recent efforts have improved 
access to these reagents (14,37).  
ENZYME-MEDIATED FUNCTIONALIZATION METHODS 
Beyond chemically-mediated transformations, several groups have begun to adapt the exquisite 
specificity and selectivity of enzymes for antibody (protein) functionalization and radiotracer 
synthesis. A wide array of enzyme-mediated reactions are available,(14) but three examples that 
have already been utilized in radiochemistry include applications of transglutaminase,(4,38) 
glycan modification(8,39–42) with multi-step transformations employing -2,6-sialyltransferase, 
-1,4-galactosidase and mutated -1,4-galactosyltransferase, as well as sortase-A mediated 
conjugation using proteins engineered to express the LPXTG tags (Fig. 4) (25,43,44). 
Conjugation reactions involving transglutaminase can occur at native Q295 glutamine 
residues in the CH2 domain of IgG1 antibodies (Fig. 4A). Alternatively, site-specific derivatization 
can be achieved at engineered protein tags (so-called ‘Q-tags’) which harbor a recognition 
sequence and an accessible glutamine residue that acts as a substrate for mutated transglutaminase 
enzymes (45). 
Most antibodies are inherently glycoproteins (Fig. 1). Therefore, glycoengineering offers 
a fascinating approach for site-selective modification of antibodies. Different strategies for 
modifying glycans exist but the general features include, i) an enzymatic ‘cleaning step’ to 
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homogenize the presentation of glycans on the antibody sample, followed by ii) enzyme-mediated 
conjugation using a non-native substrate bearing either a bioorthogonal reactive group or a chelate 
for subsequent radiolabeling (Fig. 4B). Using this approach, Zeglis and co-workers reported a 
number of interesting applications ranging from pretargeted immuno-PET through to the synthesis 
of functionalized antibodies for multi-modal (PET and optical) imaging (41).  
There is no doubt that the aforementioned examples of enzyme-mediated chemistry are 
elegant approaches to functionalize antibodies. However, for future clinical applications, it is 
crucial to ensure complete removal of the enzyme from the desired protein conjugate. Arguably 
one of the most exciting strategies involves the use of sortase-A transpeptidase (Fig. 4C). This 
approach is conceptually more challenging, because from the outset it involves the use of 
engineered proteins that display a specific LPXTG sequence. However, this tag guarantees site-
selective functionalization. For example, Paterson et al. reported the use of sortase-A to couple a 
sarcophogine chelate (derivatized with a short polyethylene glycol linker and an N-terminal 
triglycine (Gly)3 group) to an scFv fragment that targets the ligand-induced binding sites (LIBS) 
on the glycoprotein receptor GPIIb/IIIa (43). An additional feature of sortase-A conjugation is that 
the reactive components, including the sortase-A enzyme can be co-engineered to display a (His)6-
tag sequence which facilitates purification using standard affinity chromatography (44). If 
successful protein conjugation occurs, the (His)6-tag can be designed to be automatically cleaved 
from the product (e.g. using augmented recognition C-terminal sequences such as LPXTG-(His)6). 
At the same time, unreacted reagents retain their original (His)6-tag and byproducts receive a 
(His)6-tag via an exchange mechanism. Hence, purification of the desired protein from reagents 
and unwanted byproducts is a ‘built-in’ part of the sortase-A process.  
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Finally, it is worth noting that alternative conjugation strategies involving engineered 
fusion proteins exist (46–48). Here, the most familiar example involves fusion of streptavidin (53 
kDa) to a protein of interest followed by site-specific conjugation with a substrate bearing a biotin-
tag. However, other promising approaches include the use of SNAP-tag (~19 kDa), CLIP-tag (~19 
kDa) and HaloTag (33 kDa) enzymes (Fig. 5). SNAP-tags and CLIP tags accept work via the same 
mechanism. Knight et al. used the HaloTag approach combined with an 111In-radiolabeled 
complex to pretarget the non-internalizing TAG-72 biomarker expressed on LS174T colorectal 
cancer cells (48). Metal binding chelates featuring a fluorescence label and an alkylchloride group 
– which forms a covalent bond with the HaloTag enzyme – were developed. From a pretargeting
perspective, HaloTags were found to be sufficiently reactive to allow specific accumulation in 
tumors. However, incorporation of long-chain aliphatic handles on the chelate component may 
potentially alter the lipophilicity and pharmacokinetic distribution of the reagents in vivo. In 
addition, fusion of larger proteins to an antibody has the potential to alter the distribution profile. 
Nevertheless, excellent tumor localization of the radioactivity was achieved in tumor-bearing 
mice. With further optimization, HaloTags and related fusion proteins will undoubtedly allow 
expansion of this technology to other substrates and targeting vectors.  
CONCLUSIONS AND FUTURE DIRECTIONS 
A wide range of alternative conjugation methods are making their way into the radiochemical 
sciences. Strategies involving bioorthogonal chemistry, photochemistry and enzyme-mediated 
processes all show promise for future radiotracer design. These new methods allow researchers to 
construct peptide- and protein-based radiotracers with unprecedented control over the chemo-
selectivity and regio-selectivity of the conjugation step. Advances in site-specific conjugation 
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allow new immuno-PET tracers to be synthesized while minimizing the risk of compromising the 
distribution profile and immunoreactivity of the antibody or biomolecule by avoiding modification 
at undesirable sites. As new technologies are developed, it is worth keeping in mind that existing 
methods (namely, non-specific cysteine and lysine functionalization) are simple, work efficiently 
for standard antibodies, and are already part of routine clinical translation. Therefore, any 
alternative conjugation method should deliver advantages that standard non-specific chemistry 
cannot provide. Ideally, new methods should also be applicable to a diverse range of cancer 
targeting proteins. In this respect, selected chemistries described in this article have the potential 
to change the way which radiotracers are designed and produced, and may expand the range of 
immuno-PET for clinical imaging. It will be exciting to see how these technologies advance in the 
coming years. 
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Figure 1. Structural features of a generic IgG1 human antibody showing the various domains of 
the heavy and light chains, the antigen binding (CDR = complementary determining region), the 
Fab fragment, the crystallizable fragment (Fc), and the location of glycosylated residues. Reaction 
sites include (but are not limited to): (1) cysteine or reduced disulfides, (2) lysine functionalization, 
(3) C- or N-terminal chemistry, including the use of exogenous engineered sequences such as His6, 
Myc-tag, HaloTag or SNAP-tags etc, (4) transglutaminase coupling, (5) enzyme-mediated glycan 
modification, and (6) bispecific antibodies with one arm selective for a metal ion complex and the 
other for the target of interest. 
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Figure 2. Illustration of some of the classic and modern chemical reactions for protein ligation. 
Note that the figure is not intended to be comprehensive but rather gives a flavor of the different 
types of reagents and transformations that are potentially useful in protein-based radiotracers 
synthesis.  
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Figure 3. Comparison of PET images recorded in athymic nude mice that were administered with 
either (left) [89Zr]ZrDFO-azepin-trastuzumab synthesized by a photochemical conjugation and 
radiolabeling process (unpublished data), and (right) [89Zr]ZrDFO-Nsucc-trastuzumab synthesized 
via a conventional thermochemical route using N-succinyl (Nsucc) activated ester chemistry (33). 
No discernable differences were observed when comparing the PET images or the biodistribution 
data for the two radiotracers produced via different the photochemical or thermochemical routes.  
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Figure 4. Representative examples of enzyme-mediated protein ligation reactions. (A) 
Transglutaminase reaction using primary amine substrates and either natural or engineered 
glutamine residues. (B) Multi-step glycan modification. (C) Site-specific sortase-A mediated 
conjugation using the LPXTG tag (where X = any amino acid and the coupled substrate contains 
an N-terminal poly-glycine handle.  
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Figure 5. Illustration of the substrates and covalent bioconjugation reactions on fusion proteins 
involving, (A) the use of SNAP-tags or CLIP-tags with benzylguanosyl (BG) and benzylcytosyl 
(BC) substrates, respectively, and (B) covalent bond formation between the Asp106 residue in the 
mutated active site of a HaloTag and an 111In-radiolabeled alkylchloride substrate (111In-HTL-1) 
(48). 
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